Review of the Evidence for Pulmonary Rehabilitation in COPD: Clinical Benefits and Cost-Effectiveness

REFERENCES

1. 1.↵
   1. Mannino DM,
   2. Homa DM,
   3. Akinbami LJ,
   4. Ford ES,
   5. Redd SC

   . Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. MMWR Surveill Summ 2002;51(6):1-16.

   OpenUrlPubMed
2. 2.↵
   1. Buist AS,
   2. McBurnie MA,
   3. Vollmer WM,
   4. Gillespie S,
   5. Burney P,
   6. Mannino DM,
   7. et al

   ; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370(9589):741-750.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. McCarthy B,
   2. Casey D,
   3. Devane D,
   4. Murphy K,
   5. Murphy E,
   6. Lacasse Y

   . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;2015(2):Cd003793.

   OpenUrl
4. 4.↵
   1. Puhan MA,
   2. Gimeno-Santos E,
   3. Cates CJ,
   4. Troosters T

   . Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016;12(12):Cd005305.

   OpenUrlPubMed
5. 5.↵
   1. Ryrsø CK,
   2. Godtfredsen NS,
   3. Kofod LM,
   4. Lavesen M,
   5. Mogensen L,
   6. Tobberup R,
   7. et al

   . Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med 2018;18(1):154.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Stefan MS,
   2. Pekow PS,
   3. Priya A,
   4. ZuWallack R,
   5. Spitzer KA,
   6. Lagu TC,
   7. et al

   . Association between initiation of pulmonary rehabilitation and rehospitalizations in patients hospitalized with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2021;204(9):1015-1023.

   OpenUrlPubMed
7. 7.↵
   1. Lindenauer PK,
   2. Stefan MS,
   3. Pekow PS,
   4. Mazor KM,
   5. Priya A,
   6. Spitzer KA,
   7. et al

   . Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among Medicare beneficiaries. JAMA 2020;323(18):1813-1823.

   OpenUrlPubMed
8. 8.↵
   1. Nishi SP,
   2. Zhang W,
   3. Kuo YF,
   4. Sharma G

   . Pulmonary rehabilitation utilization in older adults with chronic obstructive pulmonary disease, 2003 to 2012. J Cardiopulm Rehabil Prev 2016;36(5):375-382.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Mosher CL,
   2. Nanna MG,
   3. Jawitz OK,
   4. Raman V,
   5. Farrow NE,
   6. Aleem S,
   7. et al

   . Cost-effectiveness of pulmonary rehabilitation among US adults with chronic obstructive pulmonary disease. JAMA Netw Open 2022;5(6):e2218189.

   OpenUrl
10. 10.↵
    1. Spruit MA,
    2. Singh SJ,
    3. Garvey C,
    4. ZuWallack R,
    5. Nici L,
    6. Rochester C,
    7. et al

    .; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188(8):e13-64-e64.

    OpenUrl
11. 11.↵
    1. Maltais F,
    2. LeBlanc P,
    3. Simard C,
    4. Jobin J,
    5. Bérubé C,
    6. Bruneau J,
    7. et al

    . Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154(2 Pt 1):442-447.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Casaburi R,
    2. Patessio A,
    3. Ioli F,
    4. Zanaboni S,
    5. Donner CF,
    6. Wasserman K

    . Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991;143(1):9-18.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Gosselink R,
    2. Troosters T,
    3. Decramer M

    . Exercise testing: why, which and how to interpret. Breathe 2004;1(2):120-129.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Holland AE,
    2. Spruit MA,
    3. Troosters T,
    4. Puhan MA,
    5. Pepin V,
    6. Saey D,
    7. et al

    . An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44(6):1428-1446.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Singh SJ,
    2. Puhan MA,
    3. Andrianopoulos V,
    4. Hernandes NA,
    5. Mitchell KE,
    6. Hill CJ,
    7. et al

    . An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014;44(6):1447-1478.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Jaeschke R,
    2. Singer J,
    3. Guyatt GH

    . Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10(4):407-415.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Evans RA,
    2. Singh SJ

    . Minimum important difference of the incremental shuttle walk test distance in patients with COPD. Thorax 2019;74(10):994-995.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Puhan MA,
    2. Chandra D,
    3. Mosenifar Z,
    4. Ries A,
    5. Make B,
    6. Hansel NN,
    7. et al

    ; National Emphysema Treatment Trial (NETT) Research Group. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011;37(4):784-790.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Donaldson GC,
    2. Seemungal TA,
    3. Bhowmik A,
    4. Wedzicha JA

    . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57(10):847-852.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Pitta F,
    2. Troosters T,
    3. Probst VS,
    4. Spruit MA,
    5. Decramer M,
    6. Gosselink R

    . Physical activity and hospitalization for exacerbation of COPD. Chest 2006;129(3):536-544.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Schlenk EA,
    2. Erlen JA,
    3. Dunbar-Jacob J,
    4. McDowell J,
    5. Engberg S,
    6. Sereika SM,
    7. et al

    . Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998;7(1):57-65.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Seemungal TA,
    2. Donaldson GC,
    3. Paul EA,
    4. Bestall JC,
    5. Jeffries DJ,
    6. Wedzicha JA

    . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(5 Pt 1):1418-1422.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Jones PW,
    2. Quirk FH,
    3. Baveystock CM

    . The St George’s Respiratory Questionnaire. Respir Med 1991;85 Suppl B:25-31.discussion 33–27.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Schünemann HJ,
    2. Griffith L,
    3. Jaeschke R,
    4. Goldstein R,
    5. Stubbing D,
    6. Guyatt GH

    . Evaluation of the minimal important difference for the feeling thermometer and the St George’s Respiratory Questionnaire in patients with chronic air flow obstruction. J Clin Epidemiol 2003;56(12):1170-1176.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Jones PW

    . St George’s Respiratory Questionnaire: MCID. COPD 2005;2(1):75-79.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Chauvin A,
    2. Rupley L,
    3. Meyers K,
    4. Johnson K,
    5. Eason J

    . Outcomes in cardiopulmonary physical therapy: chronic respiratory disease questionnaire (CRQ). Cardiopulm Phys Ther J 2008;19(2):61-67.

    OpenUrlPubMed
27. 27.↵
    1. Shah T,
    2. Press VG,
    3. Huisingh-Scheetz M,
    4. White SR

    . COPD readmissions: addressing COPD in the era of value-based health care. Chest 2016;150(4):916-926.

    OpenUrl
28. 28.↵
    1. Shah T,
    2. Churpek MM,
    3. Coca Perraillon M,
    4. Konetzka RT

    . Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. Chest 2015;147(5):1219-1226.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Jacobs DM,
    2. Noyes K,
    3. Zhao J,
    4. Gibson W,
    5. Murphy TF,
    6. Sethi S,
    7. et al

    . Early hospital readmissions after an acute exacerbation of chronic obstructive pulmonary disease in the Nationwide Readmissions Database. Ann Am Thorac Soc 2018;15(7):837-845.

    OpenUrlPubMed
30. 30.↵
    1. Lindenauer PK,
    2. Dharmarajan K,
    3. Qin L,
    4. Lin Z,
    5. Gershon AS,
    6. Krumholz HM

    . Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;197(8):1009-1017.

    OpenUrlPubMed
31. 31.↵
    1. Lee H,
    2. Shi SM,
    3. Kim DH

    . Home time as a patient-centered outcome in administrative claims data. J Am Geriatr Soc 2019;67(2):347-351.

    OpenUrlPubMed
32. 32.↵
    1. Greening NJ,
    2. Williams JE,
    3. Hussain SF,
    4. Harvey-Dunstan TC,
    5. Bankart MJ,
    6. Chaplin EJ,
    7. et al

    . An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomized controlled trial. BMJ 2014;349:g4315.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Man WD,
    2. Kon SS,
    3. Maddocks M

    . Rehabilitation after an exacerbation of chronic respiratory disease. BMJ 2014;349:g4370.

    OpenUrlFREE Full Text
34. 34.↵
    1. Wedzicha J-C,
    2. Miravitlles M,
    3. Hurst JR,
    4. Calverley PM,
    5. Albert RK,
    6. Anzueto A,
    7. et al

    . Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;49(3).
35. 35.↵
    1. Aberle DR,
    2. Adams AM,
    3. Berg CD,
    4. Black WC,
    5. Clapp JD,
    6. Fagerstrom RM,
    7. et al

    . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Halpin DM,
    2. Tashkin DP

    . Defining disease modification in chronic obstructive pulmonary disease. COPD 2009;6(3):211-225.

    OpenUrlPubMed
37. 37.↵
    1. Griffiths TL,
    2. Phillips CJ,
    3. Davies S,
    4. Burr ML,
    5. Campbell IA

    . Cost-effectiveness of an out-patient multidisciplinary pulmonary rehabilitation program. Thorax 2001;56(10):779-784.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Hoogendoorn M,
    2. van Wetering CR,
    3. Schols AM,
    4. Rutten-van Mölken MP

    . Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 2010;35(1):79-87.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Gillespie P,
    2. O’Shea E,
    3. Casey D,
    4. Murphy K,
    5. Devane D,
    6. Cooney A,
    7. et al

    ; PRINCE study team. The cost-effectiveness of a structured education pulmonary rehabilitation program for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomized trial. BMJ Open 2013;3(11):e003479.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Golmohammadi K,
    2. Jacobs P,
    3. Sin DD

    . Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary disease. Lung 2004;182(3):187-196.

    OpenUrlPubMedWeb of Science
41. 41.↵
    1. Liu S,
    2. Zhao Q,
    3. Li W,
    4. Zhao X,
    5. Li K

    . The cost-effectiveness of pulmonary rehabilitation for COPD in different settings: a systematic review. Appl Health Econ Health Policy 2021;19(3):313-324.

    OpenUrl
42. 42.↵
    1. Mosher CL,
    2. Belman M,
    3. Garvey C,
    4. Casaburi R

    . Pulmonary rehabilitation in chronic obstructive pulmonary disease: medicine’s best-kept secret that could save Medicare a billion dollars a year. Ann Am Thorac Soc 2023;20(10):1397-1399.

    OpenUrl
43. 43.↵
    1. Rochester CL,
    2. Alison JA,
    3. Carlin B,
    4. Jenkins AR,
    5. Cox NS,
    6. Bauldoff G,
    7. et al

    . Pulmonary rehabilitation for adults with chronic respiratory disease: an official American Thoracic Society Clinical Practice guideline. Am J Respir Crit Care Med 2023;208(4):e7-e26.

    OpenUrl